Standard Dosing Schedule for Keytruda
Keytruda (pembrolizumab) is administered as an intravenous infusion every 3 weeks (Q3W) or every 6 weeks (Q6W), depending on the approved indication, patient weight, and treatment duration. The standard dose is 200 mg for adults every 3 weeks or 400 mg every 6 weeks. For pediatric patients (over 26 kg), it's 2 mg/kg every 3 weeks.[1][2]
How Dosing Varies by Cancer Type
Schedules align with FDA-approved indications:
- Non-small cell lung cancer (NSCLC), melanoma, head and neck cancer: Typically every 3 weeks for up to 2 years or until disease progression.
- MSI-H/dMMR cancers or endometrial carcinoma: Every 3 weeks or 6 weeks, often combined with other therapies.
- Triple-negative breast cancer: Every 3 weeks with chemotherapy.
Duration can extend beyond 2 years in responsive cases, with re-challenges possible after breaks.[1][3]
Q3W vs. Q6W: Which Is Used When?
The Q6W schedule (400 mg) was approved as an alternative to Q3W to reduce clinic visits, with equivalent efficacy shown in pharmacokinetic studies. Q3W remains more common for combination regimens. Physicians select based on patient convenience, tumor response, and toxicity.[2][4]
What Happens During Infusion and Monitoring?
Each infusion lasts 30 minutes. Patients receive monitoring for immune-related side effects like pneumonitis or colitis, with dose delays or discontinuation if severe. Pretreatment with dexamethasone may occur for hypersensitivity risk.[1][5]
Why Frequency Might Change for Patients
Dosing adjusts for body weight under 30 kg (2 mg/kg Q3W), organ impairment, or drug interactions. In trials, about 10-20% of patients skip or delay doses due to adverse events.[3][6]
Sources
[1]: Keytruda Prescribing Information (Merck)
[2]: FDA Label for Pembrolizumab
[3]: NCCN Guidelines for NSCLC
[4]: Pharmacokinetics Study - J Clin Oncol (2021)
[5]: Keytruda HCP Site
[6]: KEYNOTE-001 Trial Data